{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:27:03Z","timestamp":1793388423956,"version":"4.5.0"},"reference-count":106,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/100000049","name":"National Institute of Aging","doi-asserted-by":"publisher","award":["AG072380-01A1"],"award-info":[{"award-number":["AG072380-01A1"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020423","name":"Texas Alzheimer\u2019s Research and Care Consortium","doi-asserted-by":"crossref","award":["TARCC 2020-23-93-II"],"award-info":[{"award-number":["TARCC 2020-23-93-II"]}],"id":[{"id":"10.13039\/100020423","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>A growing body of evidence has shown the involvement of the kynurenine\npathway (KP), the primary route of tryptophan (TRP) catabolism, in the pathophysiology of neuropsychiatric\ndisorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The study aims to provide a comprehensive and critical overview of the clinical evidence\non the KP involvement in the pathophysiology of Alzheimer\u2019s disease (AD) and Parkinson's disease\n(PD), discussing therapeutic opportunities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched for studies investigating KP metabolites in human subjects with AD and\/or PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Postmortem studies showed altered levels of KP metabolites in the brain of AD and PD patients\ncompared with controls. Cross-sectional studies have reported associations between peripheral\nlevels (serum or plasma) of KP metabolites and cognitive function in these patients, but the results are\nnot always concordant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Given the emerging evidence of the involvement of KP in the pathophysiology of neuropsychiatric\/\nneurodegenerative diseases and promising results from preclinical pharmacological studies,\na better understanding of the KP involvement in AD and PD is warranted. Future longitudinal\nstudies are needed to define the direction of the observed associations and specific therapeutic targets\nwithin the KP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570159x20666220922153221","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:29:43Z","timestamp":1663892983000},"page":"260-272","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Involvement of Kynurenine Pathway in Neurodegenerative Diseases"],"prefix":"10.2174","volume":"21","author":[{"given":"Lais B.","family":"Martins","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.M.","family":"Silveira","sequence":"additional","affiliation":[{"name":"Department of Nutrition, School of Nursing, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil"},{"name":"Department of Physiology and Pharmacology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio L.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA"},{"name":"Faculdade Santa Casa BH, Belo Horizonte, Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"Feigin V.L.","year":"2017","unstructured":"Feigin V.L.; Abajobir A.A.; Abate K.H.; Abd-Allah F.; Abdulle A.M.; Abera S.F.; Abyu G.Y.; Ahmed M.B.; Aichour A.N.; Aichour I.; Aichour M.T.E.; Akinyemi R.O.; Alabed S.; Al-Raddadi R.; Alvis-Guzman N.; Amare A.T.; Ansari H.; Anwari P.; \u00c4rnl\u00f6v J.; Asayesh H.; Asgedom S.W.; Atey T.M.; Avila-Burgos L.; Frinel E.; Avokpaho G.A.; Azarpazhooh M.R.; Barac A.; Barboza M.; Barker-Collo S.L.; B\u00e4rnighausen T.; Bedi N.; Beghi E.; Bennett D.A.; Bensenor I.M.; Berhane A.; Betsu B.D.; Bhaumik S.; Birlik S.M.; Biryukov S.; Boneya D.J.; Bulto L.N.B.; Carabin H.; Casey D.; Casta\u00f1eda-Orjuela C.A.; Catal\u00e1-L\u00f3pez F.; Chen H.; Chitheer A.A.; Chowdhury R.; Christensen H.; Dandona L.; Dandona R.; de Veber G.A.; Dharmaratne S.D.; Do H.P.; Dokova K.; Dorsey E.R.; Ellenbogen R.G.; Eskandarieh S.; Farvid M.S.; Fereshtehnejad S-M.; Fischer F.; Foreman K.J.; Geleijnse J.M.; Gillum R.F.; Giussani G.; Goldberg E.M.; Gona P.N.; Goulart A.C.; Gugnani H.C.; Gupta R.; Hachinski V.; Gupta R.; Hamadeh R.R.; Hambisa M.; Hankey G.J.; Hareri H.A.; Havmoeller R.; Hay S.I.; Heydarpour P.; Hotez P.J.; Jakovljevic M.M.B.; Javanbakht M.; Jeemon P.; Jonas J.B.; Kalkonde Y.; Kandel A.; Karch A.; Kasaeian A.; Kastor A.; Keiyoro P.N.; Khader Y.S.; Khalil I.A.; Khan E.A.; Khang Y-H.; Tawfih A.; Khoja A.; Khubchandani J.; Kulkarni C.; Kim D.; Kim Y.J.; Kivimaki M.; Kokubo Y.; Kosen S.; Kravchenko M.; Krishnamurthi R.V.; Defo B.K.; Kumar G.A.; Kumar R.; Kyu H.H.; Larsson A.; Lavados P.M.; Li Y.; Liang X.; Liben M.L.; Lo W.D.; Logroscino G.; Lotufo P.A.; Loy C.T.; Mackay M.T.; El Razek H.M.A.; El Razek M.M.A.; Majeed A.; Malekzadeh R.; Manhertz T.; Mantovani L.G.; Massano J.; Mazidi M.; McAlinden C.; Mehata S.; Mehndiratta M.M.; Memish Z.A.; Mendoza W.; Mengistie M.A.; Mensah G.A.; Meretoja A.; Mezgebe H.B.; Miller T.R.; Mishra S.R.; Ibrahim N.M.; Mohammadi A.; Mohammed K.E.; Mohammed S.; Mokdad A.H.; Moradi-Lakeh M.; Velasquez I.M.; Musa K.I.; Naghavi M.; Ngunjiri J.W.; Nguyen C.T.; Nguyen G.; Le Nguyen Q.; Nguyen T.H.; Nichols E.; Ningrum D.N.A.; Nong V.M.; Norrving B.; Noubiap J.J.N.; Ogbo F.A.; Owolabi M.O.; Pandian J.D.; Parmar P.G.; Pereira D.M.; Petzold M.; Phillips M.R.; Piradov M.A.; Poulton R.G.; Pourmalek F.; Qorbani M.; Rafay A.; Rahman M.; Rahman M.H.U.; Rai R.K.; Rajsic S.; Ranta A.; Rawaf S.; Renzaho A.M.N.; Rezai M.S.; Roth G.A.; Roshandel G.; Rubagotti E.; Sachdev P.; Safiri S.; Sahathevan R.; Sahraian M.A.; Samy A.M.; Santalucia P.; Santos I.S.; Sartorius B.; Satpathy M.; Sawhney M.; Saylan M.I.; Sepanlou S.G.; Shaikh M.A.; Shakir R.; Shamsizadeh M.; Sheth K.N.; Shigematsu M.; Shoman H.; Silva D.A.S.; Smith M.; Sobngwi E.; Sposato L.A.; Stanaway J.D.; Stein D.J.; Steiner T.J.; Stovner L.J.; Abdulkader R.S.; E.I. Szoeke; C.; Tabar\u00e9s-Seisdedos, R.; Tanne, D.; Theadom, A.M.; Thrift, A.G.; Tirschwell, D.L.; Topor-Madry, R.; Tran, B.X.; Truelsen, T.; Tuem, K.B.; Ukwaja, K.N.; Uthman, O.A.; Varakin, Y.Y.; Vasankari, T.; Venketasubramanian, N.; Vlassov, V.V.; Wadilo, F.; Wakayo, T.; Wallin, M.T.; Weiderpass, E.; Westerman, R.; Wijeratne, T.; Wiysonge, C.S.; Woldu, M.A.; Wolfe, C.D.A.; Xavier, D.; Xu, G.; Yano, Y.; Yimam, H.H.; Yonemoto, N.; Yu, C.; Zaidi, Z.; El Sayed Zaki, M.; Zunt, J.R.; Murray, C.J.L.; Vos, T. Group GBDNDC. Global, regional, and national burden of neurological disorders during 1990\u20132015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017,16(11),877-897","journal-title":"Lancet Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.3390\/ijms21072431","volume":"21","author":"Tanaka M.","year":"2020","unstructured":"Tanaka M.; Toldi J.; V\u00e9csei L.; Exploring the etiological links behind neurodegenerative diseases: Inflammatory cytokines and bioactive kynurenines. Int J Mol Sci 2020,21(7),2431","journal-title":"Int J Mol Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"Marras C.","year":"2018","unstructured":"Marras C.; Beck J.C.; Bower J.H.; Roberts E.; Ritz B.; Ross G.W.; Abbott R.D.; Savica R.; Van Den Eeden S.K.; Willis A.W.; Tanner C.M.; Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinsons Dis 2018,4(1),21","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jalz.2017.02.001","volume":"13","year":"2017","unstructured":"Alzheimer's A, 2017 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2017,13(4),325-373","journal-title":"Alzheimers Dement"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"Scheltens P.","year":"2016","unstructured":"Scheltens P.; Blennow K.; Breteler M.M.B.; de Strooper B.; Frisoni G.B.; Salloway S.; Van der Flier W.M.; Alzheimer\u2019s disease. Lancet 2016,388(10043),505-517","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"Nichols E.","year":"2022","unstructured":"Nichols E.; Steinmetz J.D.; Vollset S.E.; Fukutaki K.; Chalek J.; Abd-Allah F.; Abdoli A.; Abualhasan A.; Abu-Gharbieh E.; Akram T.T.; Al Hamad H.; Alahdab F.; Alanezi F.M.; Alipour V.; Almustanyir S.; Amu H.; Ansari I.; Arabloo J.; Ashraf T.; Astell-Burt T.; Ayano G.; Ayuso-Mateos J.L.; Baig A.A.; Barnett A.; Barrow A.; Baune B.T.; B\u00e9jot Y.; Bezabhe W.M.M.; Bezabih Y.M.; Bhagavathula A.S.; Bhaskar S.; Bhattacharyya K.; Bijani A.; Biswas A.; Bolla S.R.; Boloor A.; Brayne C.; Brenner H.; Burkart K.; Burns R.A.; C\u00e1mera L.A.; Cao C.; Carvalho F.; Castro-de-Araujo L.F.S.; Catal\u00e1-L\u00f3pez F.; Cerin E.; Chavan P.P.; Cherbuin N.; Chu D-T.; Costa V.M.; Couto R.A.S.; Dadras O.; Dai X.; Dandona L.; Dandona R.; De la Cruz-G\u00f3ngora V.; Dhamnetiya D.; Dias da Silva D.; Diaz D.; Douiri A.; Edvardsson D.; Ekholuenetale M.; El Sayed I.; El-Jaafary S.I.; Eskandari K.; Eskandarieh S.; Esmaeilnejad S.; Fares J.; Faro A.; Farooque U.; Feigin V.L.; Feng X.; Fereshtehnejad S-M.; Fernandes E.; Ferrara P.; Filip I.; Fillit H.; Fischer F.; Gaidhane S.; Galluzzo L.; Ghashghaee A.; Ghith N.; Gialluisi A.; Gilani S.A.; Glavan I-R.; Gnedovskaya E.V.; Golechha M.; Gupta R.; Gupta V.B.; Gupta V.K.; Haider M.R.; Hall B.J.; Hamidi S.; Hanif A.; Hankey G.J.; Haque S.; Hartono R.K.; Hasaballah A.I.; Hasan M.T.; Hassan A.; Hay S.I.; Hayat K.; Hegazy M.I.; Heidari G.; Heidari-Soureshjani R.; Herteliu C.; Househ M.; Hussain R.; Hwang B-F.; Iacoviello L.; Iavicoli I.; Ilesanmi O.S.; Ilic I.M.; Ilic M.D.; Irvani S.S.N.; Iso H.; Iwagami M.; Jabbarinejad R.; Jacob L.; Jain V.; Jayapal S.K.; Jayawardena R.; Jha R.P.; Jonas J.B.; Joseph N.; Kalani R.; Kandel A.; Kandel H.; Karch A.; Kasa A.S.; Kassie G.M.; Keshavarz P.; Khan M.A.B.; Khatib M.N.; Khoja T.A.M.; Khubchandani J.; Kim M.S.; Kim Y.J.; Kisa A.; Kisa S.; Kivim\u00e4ki M.; Koroshetz W.J.; Koyanagi A.; Kumar G.A.; Kumar M.; Lak H.M.; Leonardi M.; Li B.; Lim S.S.; Liu X.; Liu Y.; Logroscino G.; Lorkowski S.; Lucchetti G.; Lutzky Saute R.; Magnani F.G.; Malik A.A.; Massano J.; Mehndiratta M.M.; Menezes R.G.; Meretoja A.; Mohajer B.; Mohamed Ibrahim N.; Mohammad Y.; Mohammed A.; Mokdad A.H.; Mondello S.; Moni M.A.A.; Moniruzzaman M.; Mossie T.B.; Nagel G.; Naveed M.; Nayak V.C.; Neupane Kandel S.; Nguyen T.H.; Oancea B.; Otstavnov N.; Otstavnov S.S.; Owolabi M.O.; Panda-Jonas S.; Pashazadeh Kan F.; Pasovic M.; Patel U.K.; Pathak M.; Peres M.F.P.; Perianayagam A.; Peterson C.B.; Phillips M.R.; Pinheiro M.; Piradov M.A.; Pond C.D.; Potashman M.H.; Pottoo F.H.; Prada S.I.; Radfar A.; Raggi A.; Rahim F.; Rahman M.; Ram P.; Ranasinghe P.; Rawaf D.L.; Rawaf S.; Rezaei N.; Rezapour A.; Robinson S.R.; Romoli M.; Roshandel G.; Sahathevan R.; Sahebkar A.; Sahraian M.A.; Sathian B.; Sattin D.; Sawhney M.; Saylan M.; Schiavolin S.; Seylani A.; Sha F.; Shaikh M.A.; Shaji K.S.; Shannawaz M.; Shetty J.K.; Shigematsu M.; Shin J.I.; Shiri R.; Silva D.A.S.; Silva J.P.; Silva R.; Singh J.A.; Skryabin V.Y.; Skryabina A.A.; Smith A.E.; Soshnikov S.; Spurlock E.E.; Stein D.J.; Sun J.; Tabar\u00e9s-Seisdedos R.; Thakur B.; Timalsina B.; Tovani-Palone M.R.; Tran B.X.; Tsegaye G.W.; Valadan Tahbaz S.; Valdez P.R.; Venketasubramanian N.; Vlassov V.; Vu G.T.; Vu L.G.; Wang Y-P.; Wimo A.; Winkler A.S.; Yadav L.; Yahyazadeh Jabbari S.H.; Yamagishi K.; Yang L.; Yano Y.; Yonemoto N.; Yu C.; Yunusa I.; Zadey S.; Zastrozhin M.S.; Zastrozhina A.; Zhang Z-J.; Murray C.J.L.; Vos T.; Collaborators GBDDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022,7(2),e105-e125","journal-title":"Lancet Public Health"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"Dorsey E.R.","year":"2007","unstructured":"Dorsey E.R.; Constantinescu R.; Thompson J.P.; Biglan K.M.; Holloway R.G.; Kieburtz K.; Marshall F.J.; Ravina B.M.; Schifitto G.; Siderowf A.; Tanner C.M.; Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007,68(5),384-386","journal-title":"Neurology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrd2094","volume":"6","author":"Pangalos M.N.","year":"2007","unstructured":"Pangalos M.N.; Schechter L.E.; Hurko O.; Drug development for CNS disorders: Strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 2007,6(7),521-532","journal-title":"Nat Rev Drug Discov"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"Schwarcz R.","year":"2012","unstructured":"Schwarcz R.; Bruno J.P.; Muchowski P.J.; Wu H.Q.; Kynurenines in the mammalian brain: When physiology meets pathology. Nat Rev Neurosci 2012,13(7),465-477","journal-title":"Nat Rev Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.molmed.2013.02.007","volume":"19","author":"van der Goot A.T.","year":"2013","unstructured":"van der Goot A.T.; Nollen E.A.A.; Tryptophan metabolism: Entering the field of aging and age-related pathologies. Trends Mol Med 2013,19(6),336-344","journal-title":"Trends Mol Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.mad.2006.01.020","volume":"127","author":"Pertovaara M.","year":"2006","unstructured":"Pertovaara M.; Raitala A.; Lehtim\u00e4ki T.; Karhunen P.J.; Oja S.S.; Jylh\u00e4 M.; Hervonen A.; Hurme M.; Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality. Mech Ageing Dev 2006,127(5),497-499","journal-title":"Mech Ageing Dev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2018-02481","volume":"104","author":"Kim B.J.","year":"2019","unstructured":"Kim B.J.; Hamrick M.W.; Yoo H.J.; Lee S.H.; Kim S.J.; Koh J.M.; Isales C.M.; The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism. J Clin Endocrinol Metab 2019,104(6),2334-2342","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/aje\/kwv242","volume":"183","author":"Zuo H.","year":"2016","unstructured":"Zuo H.; Ueland P.M.; Ulvik A.; Eussen S.J.P.M.; Vollset S.E.; Nyg\u00e5rd O.; Midttun \u00d8.; Theofylaktopoulou D.; Meyer K.; Tell G.S.; Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality. Am J Epidemiol 2016,183(4),249-258","journal-title":"Am J Epidemiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","volume":"14","author":"Franceschi C.","year":"2018","unstructured":"Franceschi C.; Garagnani P.; Parini P.; Giuliani C.; Santoro A.; Inflammaging: A new immune\u2013metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018,14(10),576-590","journal-title":"Nat Rev Endocrinol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00726-010-0752-7","volume":"41","author":"Le Floc\u2019h N.","year":"2011","unstructured":"Le Floc\u2019h N.; Otten W.; Merlot E.; Tryptophan metabolism, from nutrition to potential therapeutic applications. Amino Acids 2011,41(5),1195-1205","journal-title":"Amino Acids"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/628192","volume":"2015","author":"Rocha N.P.","year":"2015","unstructured":"Rocha N.P.; de Miranda A.S.; Teixeira A.L.; Insights into neuroinflammation in Parkinson\u2019s Disease: From biomarkers to anti-inflammatory based therapies. BioMed Res Int 2015,2015,1-12","journal-title":"BioMed Res Int"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"577380","DOI":"10.1016\/j.jneuroim.2020.577380","volume":"348","author":"Valad\u00e3o P.A.C.","year":"2020","unstructured":"Valad\u00e3o P.A.C.; Santos K.B.S.; Ferreira e Vieira T.H.; Macedo e Cordeiro T.; Teixeira A.L.; Guatimosim C.; de Miranda A.S.; Inflammation in Huntington\u2019s disease: A few new twists on an old tale. J Neuroimmunol 2020,348,577380","journal-title":"J Neuroimmunol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/nyas.13712","volume":"1437","author":"Bauer M.E.","year":"2019","unstructured":"Bauer M.E.; Teixeira A.L.; Inflammation in psychiatric disorders: what comes first? Ann N Y Acad Sci 2019,1437(1),57-67","journal-title":"Ann N Y Acad Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3390\/cells9071614","volume":"9","author":"M\u00e9sz\u00e1ros \u00c1.","year":"2020","unstructured":"M\u00e9sz\u00e1ros \u00c1.; Moln\u00e1r K.; N\u00f3gr\u00e1di B.; Hern\u00e1di Z.; Ny\u00fal-T\u00f3th \u00c1.; Wilhelm I.; Krizbai I.A.; Neurovascular inflammaging in health and disease. Cells 2020,9(7),1614","journal-title":"Cells"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tem.2016.09.005","volume":"28","author":"Franceschi C.","year":"2017","unstructured":"Franceschi C.; Garagnani P.; Vitale G.; Capri M.; Salvioli S.; Inflammaging and \u2018Garb-aging\u2019. Trends Endocrinol Metab 2017,28(3),199-212","journal-title":"Trends Endocrinol Metab"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fneur.2019.00778","volume":"10","author":"Colpo G.D.","year":"2019","unstructured":"Colpo G.D.; Venna V.R.; McCullough L.D.; Teixeira A.L.; Systematic review on the involvement of the kynurenine pathway in stroke: Pre-clinical and clinical evidence. Front Neurol 2019,10,778","journal-title":"Front Neurol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neuroscience.2017.10.006","volume":"367","author":"Sathyasaikumar K.V.","year":"2017","unstructured":"Sathyasaikumar K.V.; Tararina M.; Wu H.Q.; Neale S.A.; Weisz F.; Salt T.E.; Schwarcz R.; Xanthurenic acid formation from 3-hydroxykynurenine in the mammalian brain: Neurochemical characterization and physiological effects. Neuroscience 2017,367,85-97","journal-title":"Neuroscience"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"43642","DOI":"10.1038\/srep43642","volume":"7","author":"Baranyi A.","year":"2017","unstructured":"Baranyi A.; Amouzadeh-Ghadikolai O.; Lewinski D.; Breitenecker R.J.; Stojakovic T.; M\u00e4rz W.; Robier C.; Rothenh\u00e4usler H.B.; Mangge H.; Meinitzer A.; Beta-trace protein as a new non-invasive immunological marker for quinolinic acid-induced impaired blood-brain barrier integrity. Sci Rep 2017,7(1),43642","journal-title":"Sci Rep"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/ejn.13499","volume":"45","author":"Hernandez-Martinez J.M.","year":"2017","unstructured":"Hernandez-Martinez J.M.; Forrest C.M.; Darlington L.G.; Smith R.A.; Stone T.W.; Quinolinic acid induces neuritogenesis in SH-SY5Y neuroblastoma cells independently of NMDA receptor activation. Eur J Neurosci 2017,45(5),700-711","journal-title":"Eur J Neurosci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"17799","DOI":"10.1038\/srep17799","volume":"5","author":"Fazio F.","year":"2016","unstructured":"Fazio F.; Lionetto L.; Curto M.; Iacovelli L.; Cavallari M.; Zappulla C.; Ulivieri M.; Napoletano F.; Capi M.; Corigliano V.; Scaccianoce S.; Caruso A.; Miele J.; De Fusco A.; Di Menna L.; Comparelli A.; De Carolis A.; Gradini R.; Nistic\u00f2 R.; De Blasi A.; Girardi P.; Bruno V.; Battaglia G.; Nicoletti F.; Simmaco M.; Xanthurenic acid activates mGlu2\/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep 2016,5(1),17799","journal-title":"Sci Rep"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuropharm.2014.02.011","volume":"81","author":"Fazio F.","year":"2014","unstructured":"Fazio F.; Zappulla C.; Notartomaso S.; Busceti C.; Bessede A.; Scarselli P.; Vacca C.; Gargaro M.; Volpi C.; Allegrucci M.; Lionetto L.; Simmaco M.; Belladonna M.L.; Nicoletti F.; Fallarino F.; Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice. Neuropharmacology 2014,81,237-243","journal-title":"Neuropharmacology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/schbul\/sbaa074","volume":"46","author":"Ulivieri M.","year":"2020","unstructured":"Ulivieri M.; Wiero\u0144ska, J.M.; Lionetto, L.; Martinello, K.; Cieslik, P.; Chocyk, A.; Curto, M.; Di Menna, L.; Iacovelli, L.; Traficante, A.; Liberatore, F.; Mascio, G.; Antenucci, N.; Giannino, G.; Vergassola, M.; Pittaluga, A.; Bruno, V.; Battaglia, G.; Fucile, S.; Simmaco, M.; Nicoletti, F.; Pilc, A.; Fazio, F. The trace kynurenine, cinnabarinic acid, displays potent antipsychotic-like activity in mice and its levels are reduced in the prefrontal cortex of individuals affected by schizophrenia. Schizophr Bull 2020,46(6),1471-1481","journal-title":"Schizophr Bull"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2016.06.020","volume":"112","author":"Fazio F","year":"2017","unstructured":"Fazio F; Lionetto L; Curto M; Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors. Neuropharmacol 2017,112(Pt B),365-72","journal-title":"Neuropharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/npp.2013.4","volume":"38","author":"Neale S.A.","year":"2013","unstructured":"Neale S.A.; Copeland C.S.; Uebele V.N.; Thomson F.J.; Salt T.E.; Modulation of hippocampal synaptic transmission by the kynurenine pathway member xanthurenic acid and other VGLUT inhibitors. Neuropsychopharmacol 2013,38(6),1060-1067","journal-title":"Neuropsychopharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/164_2016_103","volume":"239","author":"Terry N.","year":"2016","unstructured":"Terry N.; Margolis K.G.; Serotonergic mechanisms regulating the gi tract: experimental evidence and therapeutic relevance. Handb Exp Pharmacol 2016,239,319-342","journal-title":"Handb Exp Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/B978-0-12-819975-6.00022-4","volume":"179","author":"Oishi A.","year":"2021","unstructured":"Oishi A.; Gbahou F.; Jockers R.; Melatonin receptors, brain functions, and therapies. Handb Clin Neurol 2021,179,345-356","journal-title":"Handb Clin Neurol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.06.010","volume":"99","author":"Rodr\u00edguez J.J.","year":"2012","unstructured":"Rodr\u00edguez J.J.; Noristani H.N.; Verkhratsky A.; The serotonergic system in ageing and Alzheimer\u2019s disease. Prog Neurobiol 2012,99(1),15-41","journal-title":"Prog Neurobiol"},{"key":"ref=33","first-page":"323","volume":"84","author":"Liu R.Y.","year":"1999","unstructured":"Liu R.Y.; Zhou J.N.; van Heerikhuize J.; Hofman M.A.; Swaab D.F.; Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer\u2019s disease, and apolipoprotein E-epsilon4\/4 genotype. J Clin Endocrinol Metab 1999,84(1),323-327","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.3390\/ijms22136737","volume":"22","author":"Behl T.","year":"2021","unstructured":"Behl T.; Kaur I.; Sehgal A.; Singh S.; Bhatia S.; Al-Harrasi A.; Zengin G.; Bumbu A.G.; Andronie-Cioara F.L.; Nechifor A.C.; Gitea D.; Bungau A.F.; Toma M.M.; Bungau S.G.; The footprint of kynurenine pathway in neurodegeneration: Janus-faced role in Parkinson\u2019s disorder and therapeutic implications. Int J Mol Sci 2021,22(13),6737","journal-title":"Int J Mol Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.jalz.2013.12.010","volume":"10","author":"Ferreira S.T.","year":"2014","unstructured":"Ferreira S.T.; Clarke J.R.; Bomfim T.R.; De Felice F.G.; Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer\u2019s disease. Alzheimers Dement 2014,10(1S)(Suppl.),S76-S83","journal-title":"Alzheimers Dement"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/19490976.2019.1638722","volume":"11","author":"Parker A.","year":"2020","unstructured":"Parker A.; Fonseca S.; Carding S.R.; Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health. Gut Microbes 2020,11(2),135-157","journal-title":"Gut Microbes"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41582-018-0070-3","volume":"14","author":"Kivipelto M.","year":"2018","unstructured":"Kivipelto M.; Mangialasche F.; Ngandu T.; Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol 2018,14(11),653-666","journal-title":"Nat Rev Neurol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"Sperling R.","year":"2014","unstructured":"Sperling R.; Mormino E.; Johnson K.; The evolution of preclinical Alzheimer\u2019s disease: Implications for prevention trials. Neuron 2014,84(3),608-622","journal-title":"Neuron"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1097\/00001756-200312190-00005","volume":"14","author":"Guillemin G.J.","year":"2003","unstructured":"Guillemin G.J.; Smythe, G.A.; Veas, L.A.; Takikawa, O.; Brew, B.J. A\u03b21-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 2003,14(18),2311-2315","journal-title":"Neuroreport"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2990.2005.00655.x","volume":"31","author":"Guillemin G.J.","year":"2005","unstructured":"Guillemin G.J.; Brew B.J.; Noonan C.E.; Takikawa O.; Cullen K.M.; Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer\u2019s disease hippocampus. Neuropathol Appl Neurobiol 2005,31(4),395-404","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e59749","DOI":"10.1371\/journal.pone.0059749","volume":"8","author":"Wu W.","year":"2013","unstructured":"Wu W.; Nicolazzo J.A.; Wen L.; Chung R.; Stankovic R.; Bao S.S.; Lim C.K.; Brew B.J.; Cullen K.M.; Guillemin G.J.; Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer\u2019s disease brain. PLoS One 2013,8(4),e59749","journal-title":"PLoS One"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1179\/174329210X12650506623645","volume":"15","author":"Bonda D.J.","year":"2010","unstructured":"Bonda D.J.; Mailankot M.; Stone J.G.; Garrett M.R.; Staniszewska M.; Castellani R.J.; Siedlak S.L.; Zhu X.; Lee H.; Perry G.; Nagaraj R.H.; Smith M.A.; Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer\u2019s disease. Redox Rep 2010,15(4),161-168","journal-title":"Redox Rep"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13195-019-0551-7","volume":"11","author":"van der Velpen V.","year":"2019","unstructured":"van der Velpen V.; Teav T.; Gallart-Ayala H.; Mehl F.; Konz I.; Clark C.; Oikonomidi A.; Peyratout G.; Henry H.; Delorenzi M.; Ivanisevic J.; Popp J.; Systemic and central nervous system metabolic alterations in Alzheimer\u2019s disease. Alzheimers Res Ther 2019,11(1),93","journal-title":"Alzheimers Res Ther"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/biom10040571","volume":"10","author":"Gonz\u00e1lez-S\u00e1nchez M.","year":"2020","unstructured":"Gonz\u00e1lez-S\u00e1nchez M.; Jim\u00e9nez J.; Narv\u00e1ez A.; Antequera D.; Llamas-Velasco S.; Mart\u00edn A.H.S.; Molina Arjona J.A.; L\u00f3pez de Munain A.; Lle\u00f3 Bisa A.; Marco M.P.; Rodr\u00edguez-N\u00fa\u00f1ez M.; P\u00e9rez-Mart\u00ednez D.A.; Villarejo-Galende A.; Bartolome F.; Dom\u00ednguez E.; Carro E.; Kynurenic acid levels are increased in the CSF of Alzheimer\u2019s Disease patients. Biomolecules 2020,10(4),571","journal-title":"Biomolecules"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2019.03.015","volume":"80","author":"Jacobs K.R.","year":"2019","unstructured":"Jacobs K.R.; Lim C.K.; Blennow K.; Zetterberg H.; Chatterjee P.; Martins R.N.; Brew B.J.; Guillemin G.J.; Lovejoy D.B.; Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer\u2019s disease and relationship to amyloid-\u03b2 and tau. Neurobiol Aging 2019,80,11-20","journal-title":"Neurobiol Aging"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"Karikari T.K.","year":"2020","unstructured":"Karikari T.K.; Pascoal T.A.; Ashton N.J.; Janelidze S.; Benedet A.L.; Rodriguez J.L.; Chamoun M.; Savard M.; Kang M.S.; Therriault J.; Sch\u00f6ll M.; Massarweh G.; Soucy J.P.; H\u00f6glund K.; Brinkmalm G.; Mattsson N.; Palmqvist S.; Gauthier S.; Stomrud E.; Zetterberg H.; Hansson O.; Rosa-Neto P.; Blennow K.; Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 2020,19(5),422-433","journal-title":"Lancet Neurol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"9338","DOI":"10.3390\/ijms21249338","volume":"21","author":"T\u00f6r\u00f6k N.","year":"2020","unstructured":"T\u00f6r\u00f6k N.; Tanaka M.; V\u00e9csei L.; Searching for peripheral biomarkers in neurodegenerative diseases: The tryptophan-kynurenine metabolic pathway. Int J Mol Sci 2020,21(24),9338","journal-title":"Int J Mol Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"716980","DOI":"10.3389\/fimmu.2021.716980","volume":"12","author":"Skorobogatov K.","year":"2021","unstructured":"Skorobogatov K.; De Picker L.; Verkerk R.; Coppens V.; Leboyer M.; M\u00fcller N.; Morrens M.; Brain versus blood: A systematic review on the concordance between peripheral and central kynurenine pathway measures in psychiatric disorders. Front Immunol 2021,12,716980","journal-title":"Front Immunol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JAD-170485","volume":"60","author":"Giil L.M.","year":"2017","unstructured":"Giil L.M.; Midttun \u00d8.; Refsum H.; Ulvik A.; Advani R.; Smith A.D.; Ueland P.M.; Kynurenine pathway metabolites in Alzheimer\u2019s Disease. J Alzheimers Dis 2017,60(2),495-504","journal-title":"J Alzheimers Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2478\/v10039-010-0023-6","volume":"55","author":"Gulaj E.","year":"2010","unstructured":"Gulaj E.; Pawlak K.; Bien B.; Pawlak D.; Kynurenine and its metabolites in Alzheimer\u2019s disease patients. Adv Med Sci 2010,55(2),204-211","journal-title":"Adv Med Sci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s007020050029","volume":"107","author":"Widner B.","year":"2000","unstructured":"Widner B.; Leblhuber F.; Walli J.; Tilz G.P.; Demel U.; Fuchs D.; Tryptophan degradation and immune activation in Alzheimer\u2019s disease. J Neural Transm (Vienna) 2000,107(3),343-353","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1038\/s41598-018-25968-7","volume":"8","author":"Chatterjee P.","year":"2018","unstructured":"Chatterjee P.; Goozee K.; Lim C.K.; James I.; Shen K.; Jacobs K.R.; Sohrabi H.R.; Shah T.; Asih P.R.; Dave P.; ManYan C.; Taddei K.; Lovejoy D.B.; Chung R.; Guillemin G.J.; Martins R.N.; Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-\u03b2 load: A pilot study. Sci Rep 2018,8(1),8008","journal-title":"Sci Rep"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/jnc.14843","volume":"151","author":"Sorgdrager F.J.H.","year":"2019","unstructured":"Sorgdrager F.J.H.; Vermeiren Y.; Faassen M.; Ley C.; Nollen E.A.A.; Kema I.P.; De Deyn P.P.; Age\u2010 and disease\u2010specific changes of the kynurenine pathway in Parkinson\u2019s and Alzheimer\u2019s disease. J Neurochem 2019,151(5),656-668","journal-title":"J Neurochem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.schres.2020.09.007","volume":"223","author":"Morrens M.","year":"2020","unstructured":"Morrens M.; De Picker L.; Kampen J.K.; Coppens V.; Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis. Schizophr Res 2020,223,43-52","journal-title":"Schizophr Res"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1","author":"Kouli A.","year":"2018","unstructured":"Kouli A.; Torsney K.M.; Kuan W.L.; Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects. Brisbane (AU): Codon Publications; Chapter 1. Available from: 2018"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","volume":"363","author":"Samii A.","year":"2004","unstructured":"Samii A.; Nutt J.G.; Ransom B.R.; Parkinson\u2019s disease. Lancet 2004,363(9423),1783-1793","journal-title":"Lancet"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1212\/WNL.42.9.1702","volume":"42","author":"Ogawa T.","year":"1992","unstructured":"Ogawa T.; Matson W.R.; Beal M.F.; Myers R.H.; Bird E.D.; Milbury P.; Saso S.; Kynurenine pathway abnormalities in Parkinson\u2019s disease. Neurology 1992,42(9),1702-1706","journal-title":"Neurology"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/mds.28202","volume":"35","author":"Heilman P.L.","year":"2020","unstructured":"Heilman P.L.; Wang E.W.; Lewis M.M.; Krzyzanowski S.; Capan C.D.; Burmeister A.R.; Du G.; Escobar Galvis M.L.; Brundin P.; Huang X.; Brundin L.; Tryptophan metabolites are associated with symptoms and nigral pathology in Parkinson\u2019s Disease. Mov Disord 2020,35(11),2028-2037","journal-title":"Mov Disord"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1007\/s12035-017-0845-3","volume":"55","author":"Chang K.H.","year":"2018","unstructured":"Chang K.H.; Cheng M.L.; Tang H.Y.; Huang C.Y.; Wu Y.R.; Chen C.M.; Alternations of metabolic profile and kynurenine metabolism in the plasma of Parkinson\u2019s Disease. Mol Neurobiol 2018,55(8),6319-6328","journal-title":"Mol Neurobiol"},{"key":"ref=60","volume":"1","author":"Oxenkrug G.","year":"2017","unstructured":"Oxenkrug G.; van der Hart M.; Roeser J.; Summergrad P.; Peripheral Tryptophan-Kynurenine metabolism associated with metabolic syndrome is different in Parkinson\u2019s and Alzheimer\u2019s diseases. Endocrinol Diabetes Metab J 2017,1(4)","journal-title":"Endocrinol Diabetes Metab J"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s007020200014","volume":"109","author":"Widner B.","year":"2002","unstructured":"Widner B.; Leblhuber F.; Fuchs D.; Increased neopterin production and tryptophan degradation in advanced Parkinson\u2019s disease. J Neural Transm (Vienna) 2002,109(2),181-189","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10072-020-04589-x","volume":"42","author":"Bai J.","year":"2021","unstructured":"Bai J.; Zheng Y.; Yu Y.; Urinary kynurenine as a biomarker for Parkinson\u2019s disease. Neurol Sci 2021,42(2),697-703","journal-title":"Neurol Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2005.07.006","volume":"239","author":"Hartai Z.","year":"2005","unstructured":"Hartai Z.; Klivenyi P.; Janaky T.; Penke B.; Dux L.; Vecsei L.; Kynurenine metabolism in plasma and in red blood cells in Parkinson\u2019s disease. J Neurol Sci 2005,239(1),31-35","journal-title":"J Neurol Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/pr500807t","volume":"14","author":"Luan H.","year":"2015","unstructured":"Luan H.; Liu L.F.; Meng N.; Tang Z.; Chua K.K.; Chen L.L.; Song J.X.; Mok V.C.T.; Xie L.X.; Li M.; Cai Z.; LC-MS-based urinary metabolite signatures in idiopathic Parkinson\u2019s disease. J Proteome Res 2015,14(1),467-478","journal-title":"J Proteome Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0304-3940(92)90322-X","volume":"141","author":"Tohgi H.","year":"1992","unstructured":"Tohgi H.; Abe T.; Takahashi S.; Kimura M.; Takahashi J.; Kikuchi T.; Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci Lett 1992,141(1),9-12","journal-title":"Neurosci Lett"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0304-3940(93)90111-W","volume":"150","author":"Tohgi H.","year":"1993","unstructured":"Tohgi H.; Abe T.; Takahashi S.; Takahashi J.; Hamato H.; Concentrations of serotonin and its related substances in the cerebrospinal fluid of Parkinsonian patients and their relations to the severity of symptoms. Neurosci Lett 1993,150(1),71-74","journal-title":"Neurosci Lett"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"108702","DOI":"10.1016\/j.abb.2020.108702","volume":"697","author":"Zhang S.","year":"2021","unstructured":"Zhang S.; Collier M.E.W.; Heyes D.J.; Giorgini F.; Scrutton N.S.; Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases. Arch Biochem Biophys 2021,697,108702","journal-title":"Arch Biochem Biophys"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-444-63233-3.00017-8","volume":"147","author":"Ghosh R.","year":"2018","unstructured":"Ghosh R.; Tabrizi S.J.; Huntington disease. Handb Clin Neurol 2018,147,255-278","journal-title":"Handb Clin Neurol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/ng1542","volume":"37","author":"Giorgini F.","year":"2005","unstructured":"Giorgini F.; Guidetti P.; Nguyen Q.; Bennett S.C.; Muchowski P.J.; A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005,37(5),526-531","journal-title":"Nat Genet"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1073\/pnas.1604453113","volume":"113","author":"Breda C.","year":"2016","unstructured":"Breda C.; Sathyasaikumar K.V.; Sograte Idrissi S.; Notarangelo F.M.; Estranero J.G.; Moore G.G.L.; Green E.W.; Kyriacou C.P.; Schwarcz R.; Giorgini F.; Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proc Natl Acad Sci USA 2016,113(19),5435-5440","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","volume":"145","author":"Zwilling D.","year":"2011","unstructured":"Zwilling D.; Huang S.Y.; Sathyasaikumar K.V.; Notarangelo F.M.; Guidetti P.; Wu H.Q.; Lee J.; Truong J.; Andrews-Zwilling Y.; Hsieh E.W.; Louie J.Y.; Wu T.; Scearce-Levie K.; Patrick C.; Adame A.; Giorgini F.; Moussaoui S.; Laue G.; Rassoulpour A.; Flik G.; Huang Y.; Muchowski J.M.; Masliah E.; Schwarcz R.; Muchowski P.J.; Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011,145(6),863-874","journal-title":"Cell"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1124\/dmd.112.046532","volume":"40","author":"Beconi M.G.","year":"2012","unstructured":"Beconi M.G.; Yates D.; Lyons K.; Matthews K.; Clifton S.; Mead T.; Prime M.; Winkler D.; O\u2019Connell C.; Walter D.; Toledo-Sherman L.; Munoz-Sanjuan I.; Dominguez C.; Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048. Drug Metab Dispos 2012,40(12),2297-2306","journal-title":"Drug Metab Dispos"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1021\/jm970467t","volume":"40","author":"R\u00f6ver S.","year":"1997","unstructured":"R\u00f6ver S.; Cesura A.M.; Huguenin P.; Kettler R.; Szente A.; Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 1997,40(26),4378-4385","journal-title":"J Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.neuro.2021.03.009","volume":"84","author":"Sodhi R.K.","year":"2021","unstructured":"Sodhi R.K.; Bansal Y.; Singh R.; Saroj P.; Bhandari R.; Kumar B.; Kuhad A.; IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson\u2019s disease. Neurotoxicology 2021,84,184-197","journal-title":"Neurotoxicology"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"702048","DOI":"10.3389\/fimmu.2021.702048","volume":"12","author":"Marim F.M.","year":"2021","unstructured":"Marim F.M.; Teixeira D.C.; Queiroz-Junior C.M.; Valiate B.V.S.; Alves-Filho J.C.; Cunha T.M.; Dantzer R.; Teixeira M.M.; Teixeira A.L.; Costa V.V.; Inhibition of tryptophan catabolism is associated with neuroprotection during zika virus infection. Front Immunol 2021,12,702048","journal-title":"Front Immunol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"121018","DOI":"10.1016\/j.biomaterials.2021.121018","volume":"276","author":"Guo Y.","year":"2021","unstructured":"Guo Y.; Liu Y.; Wu W.; Ling D.; Zhang Q.; Zhao P.; Hu X.; Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy. Biomaterials 2021,276,121018","journal-title":"Biomaterials"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tips.2020.11.006","volume":"42","author":"Modoux M.","year":"2021","unstructured":"Modoux M.; Rolhion N.; Mani S.; Sokol H.; Tryptophan metabolism as a pharmacological target. Trends Pharmacol Sci 2021,42(1),60-73","journal-title":"Trends Pharmacol Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.3390\/cells10102729","volume":"10","author":"Ojo E.S.","year":"2021","unstructured":"Ojo E.S.; Tischkau S.A.; The role of AhR in the hallmarks of brain aging: Friend and foe. Cells 2021,10(10),2729","journal-title":"Cells"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1080\/10408398.2019.1598334","volume":"60","author":"Sun M.","year":"2020","unstructured":"Sun M.; Ma N.; He T.; Johnston L.J.; Ma X.; Tryptophan (Trp) modulates gut homeostasis via aryl hydrocarbon receptor (AhR). Crit Rev Food Sci Nutr 2020,60(10),1760-1768","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"105314","DOI":"10.1016\/j.phrs.2020.105314","volume":"164","author":"Doifode T.","year":"2021","unstructured":"Doifode T.; Giridharan V.V.; Generoso J.S.; Bhatti G.; Collodel A.; Schulz P.E.; Forlenza O.V.; Barichello T.; The impact of the microbiota-gut-brain axis on Alzheimer\u2019s disease pathophysiology. Pharmacol Res 2021,164,105314","journal-title":"Pharmacol Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.chom.2018.05.003","volume":"23","author":"Agus A.","year":"2018","unstructured":"Agus A.; Planchais J.; Sokol H.; Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 2018,23(6),716-724","journal-title":"Cell Host Microbe"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00018-017-2674-y","volume":"75","author":"Santoro A.","year":"2018","unstructured":"Santoro A.; Ostan R.; Candela M.; Biagi E.; Brigidi P.; Capri M.; Franceschi C.; Gut microbiota changes in the extreme decades of human life: A focus on centenarians. Cell Mol Life Sci 2018,75(1),129-148","journal-title":"Cell Mol Life Sci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/1574-6976.12075","volume":"38","year":"2014","unstructured":"Rajili\u0107-Stojanovi\u0107 M.; de Vos, W.M. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev 2014,38(5),996-1047","journal-title":"FEMS Microbiol Rev"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nature11550","volume":"489","author":"Lozupone C.A.","year":"2012","unstructured":"Lozupone C.A.; Stombaugh J.I.; Gordon J.I.; Jansson J.K.; Knight R.; Diversity, stability and resilience of the human gut microbiota. Nature 2012,489(7415),220-230","journal-title":"Nature"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1126\/science.1110591","volume":"308","author":"Eckburg P.B.","year":"2005","unstructured":"Eckburg P.B.; Bik E.M.; Bernstein C.N.; Purdom E.; Dethlefsen L.; Sargent M.; Gill S.R.; Nelson K.E.; Relman D.A.; Diversity of the human intestinal microbial flora. Science 2005,308(5728),1635-1638","journal-title":"Science"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.cub.2016.04.016","volume":"26","author":"Biagi E.","year":"2016","unstructured":"Biagi E.; Franceschi C.; Rampelli S.; Severgnini M.; Ostan R.; Turroni S.; Consolandi C.; Quercia S.; Scurti M.; Monti D.; Capri M.; Brigidi P.; Candela M.; Gut microbiota and extreme longevity. Curr Biol 2016,26(11),1480-1485","journal-title":"Curr Biol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2217\/nmt-2020-0023","volume":"11","author":"Martins L.B.","year":"2021","unstructured":"Martins L.B.; Malheiros Silveira A.L.; Teixeira A.L.; The link between nutrition and Alzheimer\u2019s disease: From prevention to treatment. Neurodegener Dis Manag 2021,11(2),155-166","journal-title":"Neurodegener Dis Manag"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainres.2018.01.010","volume":"1693","author":"Liddle RA","year":"2018","unstructured":"Liddle RA; Parkinson's disease from the gut. Brain Res 2018,1693(Pt B),201-6","journal-title":"Brain Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.18632\/aging.102930","volume":"12","author":"Pluta R.","year":"2020","unstructured":"Pluta R.; U\u0142amek-Kozio\u0142 M.; Januszewski, S.; Czuczwar, S.J. Gut microbiota and pro\/prebiotics in Alzheimer\u2019s disease. Aging (Albany NY) 2020,12(6),5539-5550","journal-title":"Aging (Albany NY)"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2174\/1389200219666180813144834","volume":"15","author":"Leblhuber F.","year":"2018","unstructured":"Leblhuber F.; Steiner K.; Schuetz B.; Fuchs D.; Gostner J.M.; Probiotic supplementation in patients with Alzheimer\u2019s Dementia-an explorative intervention study. Curr Alzheimer Res 2018,15(12),1106-1113","journal-title":"Curr Alzheimer Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3945\/ajcn.113.064998","volume":"98","author":"Ulvik A.","year":"2013","unstructured":"Ulvik A.; Theofylaktopoulou D.; Midttun \u00d8.; Nyg\u00e5rd O.; Eussen S.J.P.M.; Ueland P.M.; Substrate product ratios of enzymes in the kynurenine pathway measured in plasma as indicators of functional vitamin B-6 status. Am J Clin Nutr 2013,98(4),934-940","journal-title":"Am J Clin Nutr"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3945\/jn.110.133082","volume":"141","author":"Midttun \u00d8.","year":"2011","unstructured":"Midttun \u00d8.; Ulvik A.; Ringdal Pedersen E.; Ebbing M.; Bleie \u00d8.; Schartum-Hansen H.; Nilsen R.M.; Nyg\u00e5rd O.; Ueland P.M.; Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr 2011,141(4),611-617","journal-title":"J Nutr"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/nu9010053","volume":"9","author":"Hughes C.","year":"2017","unstructured":"Hughes C.; Ward M.; Tracey F.; Hoey L.; Molloy A.; Pentieva K.; McNulty H.; B-Vitamin intake and biomarker status in relation to cognitive decline in healthy older adults in a 4-year follow-up study. Nutrients 2017,9(1),53","journal-title":"Nutrients"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jalz.2005.06.001","volume":"1","author":"Corrada M.M.","year":"2005","unstructured":"Corrada M.M.; Kawas C.H.; Hallfrisch J.; Muller D.; Brookmeyer R.; Reduced risk of Alzheimer\u2019s disease with high folate intake: The baltimore longitudinal study of aging. Alzheimers Dement 2005,1(1),11-18","journal-title":"Alzheimers Dement"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3233\/JAD-171042","volume":"62","author":"Smith A.D.","year":"2018","unstructured":"Smith A.D.; Refsum H.; Bottiglieri T.; Fenech M.; Hooshmand B.; McCaddon A.; Miller J.W.; Rosenberg I.H.; Obeid R.; Homocysteine and dementia: An international consensus statement1. J Alzheimers Dis 2018,62(2),561-570","journal-title":"J Alzheimers Dis"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/molecules25030564","volume":"25","author":"Tanaka M.","year":"2020","unstructured":"Tanaka M.; Boh\u00e1r Z.; V\u00e9csei L.; Are kynurenines accomplices or principal villains in dementia? Maintenance of kynurenine metabolism. Molecules 2020,25(3),564","journal-title":"Molecules"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/0022-510X(92)90191-M","volume":"108","author":"Flint Beal M.","year":"1992","unstructured":"Flint Beal M.; Matson W.R.; Storey E.; Milbury P.; Ryan E.A.; Ogawa T.; Bird E.D.; Kynurenic acid concentrations are reduced in Huntington\u2019s disease cerebral cortex. J Neurol Sci 1992,108(1),80-87","journal-title":"J Neurol Sci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","volume":"115","author":"Heyes M.P.","year":"1992","unstructured":"Heyes M.P.; Saito K.; Crowley J.S.; Davis L.E.; Demitrack M.A.; Der M.; Dilling L.A.; Elia J.; Kruesi M.J.P.; Lackner A.; Larsen S.A.; Lee K.; Leonard H.L.; Markey S.P.; Martin A.; Milstein S.; Mouradian M.M.; Pranzatelli M.R.; Quearry B.J.; Salazar A.; Smith M.; Strauss S.E.; Sunderland T.; Swedo S.W.; Tourtellotte W.W.; Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992,115(5),1249-1273","journal-title":"Brain"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0304-3940(92)90749-W","volume":"144","author":"Pearson S.J.","year":"1992","unstructured":"Pearson S.J.; Reynolds G.P.; Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington\u2019s disease. Neurosci Lett 1992,144(1-2),199-201","journal-title":"Neurosci Lett"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s007020050149","volume":"106","author":"Baran H.","year":"1999","unstructured":"Baran H.; Jellinger K.; Deecke L.; Kynurenine metabolism in Alzheimer\u2019s disease. J Neural Transm (Vienna) 1999,106(2),165-181","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00406-012-0384-x","volume":"263","author":"Schwarz M.J.","year":"2013","unstructured":"Schwarz M.J.; Guillemin G.J.; Teipel S.J.; Buerger K.; Hampel H.; Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimer\u2019s disease patients from controls. Eur Arch Psychiatry Clin Neurosci 2013,263(4),345-352","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jchromb.2018.05.031","volume":"1091","author":"Muguruma Y.","year":"2018","unstructured":"Muguruma Y.; Tsutsui H.; Noda T.; Akatsu H.; Inoue K.; Widely targeted metabolomics of Alzheimer\u2019s disease postmortem cerebrospinal fluid based on 9-fluorenylmethyl chloroformate derivatized ultra-high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2018,1091,53-66","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13195-020-00741-z","volume":"13","author":"Whiley L.","year":"2021","unstructured":"Whiley L.; Chappell K.E.; D\u2019Hondt E.; Lewis M.R.; Jim\u00e9nez B.; Snowden S.G.; Soininen H.; K\u0142oszewska, I.; Mecocci, P.; Tsolaki, M.; Vellas, B.; Swann, J.R.; Hye, A.; Lovestone, S.; Legido-Quigley, C.; Holmes, E. Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer\u2019s disease. Alzheimers Res Ther 2021,13(1),20","journal-title":"Alzheimers Res Ther"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bbi.2021.03.019","volume":"95","author":"Willette A.A.","year":"2021","unstructured":"Willette A.A.; Pappas C.; Hoth N.; Wang Q.; Klinedinst B.; Willette S.A.; Larsen B.; Pollpeter A.; Li T.; Le S.; Collazo-Martinez A.D.; Mochel J.P.; Allenspach K.; Dantzer R.; Inflammation, negative affect, and amyloid burden in Alzheimer\u2019s disease: Insights from the kynurenine pathway. Brain Behav Immun 2021,95,216-225","journal-title":"Brain Behav Immun"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/mds.25555","volume":"28","author":"LeWitt P.A.","year":"2013","unstructured":"LeWitt P.A.; Li J.; Lu M.; Beach T.G.; Adler C.H.; Guo L.; 3-hydroxykynurenine and other Parkinson\u2019s disease biomarkers discovered by metabolomic analysis. Mov Disord 2013,28(12),1653-1660","journal-title":"Mov Disord"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"134576","DOI":"10.1016\/j.neulet.2019.134576","volume":"714","author":"Iwaoka K.","year":"2020","unstructured":"Iwaoka K.; Otsuka C.; Maeda T.; Yamahara K.; Kato K.; Takahashi K.; Takahashi K.; Terayama Y.; Impaired metabolism of kynurenine and its metabolites in CSF of parkinson\u2019s disease. Neurosci Lett 2020,714,134576","journal-title":"Neurosci Lett"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X20666220922153221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/209106\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X20666220922153221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:25:34Z","timestamp":1693700734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/209106\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x20666220922153221","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}